Mesa Laboratories Q2 EPS $1.91 May Not Be Comparable To $0.15 Estimate, Sales $53.16M Miss $54.65M Estimate
Portfolio Pulse from Benzinga Newsdesk
Mesa Laboratories (NASDAQ:MLAB) reported Q2 earnings of $1.91 per share, beating the analyst consensus estimate of $0.15 by 1173.33 percent. However, this is a 33.68 percent decrease from the same period last year. The company's quarterly sales of $53.16 million missed the analyst consensus estimate of $54.65 million by 2.72 percent, marking a 9.50 percent decrease from the same period last year.
November 06, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Mesa Laboratories reported a significant beat on EPS estimates but missed on sales. While the EPS beat is positive, the YoY decrease in both EPS and sales could be a concern for investors.
Mesa Laboratories' Q2 results are mixed. The significant beat on EPS estimates is a positive signal, indicating better-than-expected profitability. However, the YoY decrease in both EPS and sales could be a concern for investors, suggesting potential issues with the company's growth or operational efficiency. The net impact on the stock price could be neutral in the short term as the positive and negative factors balance each other out.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100